Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D926PC00001 / TROPION-Breast02A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerDr Louise BordeleauOpen to recruitmentNCT05374512
(CCTG) IND.241 - Master ProtocolA Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerDr Nidhi Kumar-TyagiSuspended/On holdNCT05601440 (Master)
(CCTG) IND.241A / Sub-Study ALiquid-Biopsy Monitoring for Patients not yet Eligible for Screening and EnrollmentDr Nidhi Kumar-TyagiSuspended/On holdNCT05601440 (A)
(CCTG) IND.241B / Sub-Study BA Phase II Study of RP-6306 in Patients with CDK4/6-Inhibitor Treated ER+HER2- Metastatic Breast Cancer Receiving GemcitabineDr Nidhi Kumar-TyagiSuspended/On holdNCT05601440 (B)
(CCTG) IND.241C / Sub-Study CA Phase II Study of Niraparib, A PARP Inhibitor, in Patients with CDK4/6-Inhibitor Treated ER+/HER2- Metastatic Breast CancerDr Nidhi Kumar-TyagiSuspended/On holdNCT05601440 (C)
(CCTG) MA.39 / TAILOR RTA randomized trial of regional radiotherapy in Biomarker low risk node positive breast cancer (TAILOR RT)Dr Timothy WhelanOpen to recruitmentNCT03488693
(Roche) WO43919 / INAVO121A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant In Patients With Hormone Receptor positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During Or After CDK4/6 Inhibitor and Endocrine Combination TherapyDr Haider SamawiOpen to recruitmentNCT05646862
OCOG-2019-RHEALRandomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)Dr Timothy WhelanOpen to recruitmentNCT04228991
OCOG-2021-ELISAProspective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features (ELISA Study)Dr Timothy WhelanOpen to recruitmentNCT04797299
OCOG-2022-RAPID2A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)Dr Do-hoon KimOpen to recruitmentNCT05417516
Download PDF